36M+
PubMed Articles
20+
Cancer Types
Real-time
Live Search
What's Really New
Last 7 daysWeight Loss, Adverse Effects With GLP-1 Medications May Be Influenced by Genetics.
Anderer Samantha
Birth After Uterus Transplant.
Johannesson Liza, Gregg Anthony R, Samiee Kimia, Bayer Johanna et al.
Most US Health Care Workers Vaccinated for Flu, Less Than Half for COVID-19.
Anderer Samantha
Browse by Cancer Type
Latest — Last 3 months
5,358 resultsPage 1 of 179Weight Loss, Adverse Effects With GLP-1 Medications May Be Influenced by Genetics.
Anderer Samantha
This Medical News article discusses findings that genetic variants may affect patients’ responses to glucagon-like peptide-1 receptor agonists such as semaglutide and tirzepatide.
Major Meta-Analysis Links Social Media to Worse Youth Mental Health.
Schweitzer Kate
This Medical News article discusses a study linking digital media—particularly social media—use to consistent risks for children’s mental health and development.
Birth After Uterus Transplant.
Johannesson Liza, Gregg Anthony R, Samiee Kimia, Bayer Johanna et al.
This study examines maternal and obstetric risks of birth after uterus transplant and neonatal outcomes.
Most US Health Care Workers Vaccinated for Flu, Less Than Half for COVID-19.
Anderer Samantha
Stroma-Driven Neuroplasticity as a Driver of Tumor Progression.
Hondermarck Hubert, Steffens Reinhardt Luiza, Jiang Chen Chen
In this issue of Cancer Discovery, Nigri and colleagues identify myofibroblastic cancer-associated fibroblasts as drivers of sympathetic nerve recruitment and activation in pancreatic ductal adenocarcinoma. By uncovering a feedforward stromal-sympathetic circuit, the study establishes neuroplasticit...
A New Class of Molecular Glues: Double Allostery Restores KEAP1 Control of NRF2.
Hintzen Jordi C J, Burslem George M
Roy and colleagues describe VVD-065, a covalent allosteric molecular glue that binds KEAP1 at Cys151 to enhance KEAP1-CUL3 assembly, restore NRF2 ubiquitination and degradation, and selectively suppress NRF2-driven tumors by reactivating endogenous E3 ligase function. See related article by Roy et a...
Checkpoint Breaches: Unexpected Effects of Anti-PD-1 Therapy on the Blood-Brain Barrier.
Karreman Matthia A, Winkler Frank
Immune checkpoint inhibitors have revolutionized cancer therapy, and their unintended side effects relate largely to inducing autoimmunity; effects on vascular functions have only rarely been observed so far. In this issue of Cancer Discovery, a puzzling finding is reported that has divergent clinic...
Uncovering risk factors in the exposome for early-onset colorectal cancer.
Lee David J, Baca Sylvan, Ng Kimmie
Data-driven prioritization of high-risk individuals for weight loss interventions.
Demircan Kamil, Carrasco-Zanini Julia, Williamson Alice, Beuchel Carl et al.
New obesity medications have demonstrated efficacy in trials, but their real-world deployment is partly limited by the absence of approaches that identify individuals for treatment based on risks for obesity-related complications. Here we present a risk prediction model to guide prioritization of hi...
Continuously graded-doped SnO 2 for efficient n-i-p perovskite solar cells.
Wang Di, Li Saisai, Ding Zijin, Xu Jian et al.
Conventional n-i-p architecture remains a robust platform for scalable perovskite photovoltaics 1,2 , yet its steady-state efficiency has stagnated at ~26% (ref.3), lagging behind p-i-n counterparts 4 . This performance gap arises from persistent non-radiative recombination at textured electron tran...
Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.
Wang Yun, Li Chunhua, Gale Robert Peter, Liang Qi et al.
Several recent trials of new chronic lymphocytic leukemia (CLL) therapies used results of measurable residual disease (MRD)-testing as a primary endpoint assuming it is an accurate surrogate for progression-free survival (PFS) which is, itself, a surrogate endpoint for survival. But whether MRD-test...
How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?
Montoro Maria Julia, Acha Pamela, Haferlach Claudia, Chan Onyee et al.
Myelodysplastic neoplasms (MDS) with TP53 multihit alterations are associated with dismal outcomes. MDS with isolated del(5q) present favorable prognosis but is defined by the absence of TP53 multihit alterations. However, whether TP53 multihit alterations exert the same adverse impact in this genet...
Phase I trial of a heat-conditioned tumor lysate vaccine (TRIMELVax) in anti-PD-1 refractory melanoma: safety and immunological aspects (NCT06556004).
Estay Roberto, Cortés Analía, Müller Bettina, Tempio Fabián et al.
TRIMELVax is a cancer vaccine prototype derived from heat-conditioned melanoma cell lysates combined with a natural adjuvant. Preclinical studies demonstrated robust antitumor immune responses and tumor regression. We conducted a Phase I clinical trial to evaluate the safety, tolerability, immunogen...
Preoperative ctDNA and tumor volume predict colorectal cancer recurrence after metastasis resection.
Oyoshi Hidekazu, Bando Hideaki, Yamashita Riu, Kageyama Shun-Ichiro et al.
Circulating tumor DNA (ctDNA) testing in patients with colorectal cancer (CRC) has demonstrated clinical significance in various contexts, including post-curative resection. Therefore, we developed a predictive model integrating preoperative ctDNA levels with radiographic imaging to assess the risk ...
'Beyond COP' climate summit puts scientists at the centre of the action.
Lenharo Mariana
Long-lived immune cells show promise against cancer in world-first trial.
Ledford Heidi
'Make Pluto a planet again'? NASA chief revives debate that divides astronomers.
Castelvecchi Davide